FDA approves first RSV vaccine for pregnancy to protect newborns
Expectant parents could soon have another new option this fall to protect their newborns from RSV, the most common cause of hospitalization in American infants.
www.cbsnews.comHere’s a quick update on RSV vaccines based on the latest widely reported developments.
-
FDA approvals and expanded indications: In 2023 the FDA approved Arexvy for older adults (60+) to prevent RSV-associated lower respiratory tract disease, with later expansions and ongoing postmarketing monitoring. This milestone set the stage for broader vaccination strategies in the U.S.. Another product, Pfizer’s Abrysvo, was approved for use in pregnant people to protect newborns, enabling maternal immunity transfer to infants after birth. These approvals collectively expanded RSV prevention options beyond older adults to include maternal vaccination for infants and later expansions to other adult age groups.[2][3]
-
Newer vaccines and age groups: By 2025–2026, vaccine programs were extending to additional adult populations at increased risk, with regulatory bodies evaluating data for expanded age indications and non-inferiority against established older populations. For example, reports highlighted expanded indications for certain RSV vaccines to adults aged 18–49 or 50–74 who have higher risk due to comorbidities or pregnancy-related protection for newborns, reflecting a broader public health strategy to reduce RSV hospitalizations across age groups.[4][8]
-
Country-level and health-system uptake: Several countries and health systems reported high effectiveness in preventing hospitalizations with available RSV vaccines for older adults and maternal vaccination for newborn protection. For instance, UK government communications cited substantial effectiveness in preventing hospitalizations among older adults and newborns when maternal vaccination occurred at appropriate times before birth. U.S. guidance and ACIP discussions continued to shape recommendations for expanding vaccine use among adults at increased risk, with advisory committee votes supporting broader uptake in certain age bands.[6][8]
-
Ongoing evidence and monitoring: Regulators and health agencies stress the importance of ongoing postmarketing studies to monitor safety, effectiveness across diverse populations, and durability of protection across RSV seasons. This includes tracking outcomes in infants protected by maternal antibodies and in adults receiving vaccination, as well as assessing performance against evolving RSV strains.[3][2]
Illustrative example:
- If you’re a Buffalo, NY resident considering RSV vaccination for you or a pregnant family member, the current landscape supports: (a) vaccination of older adults (60+) to reduce RSV-LRTD risk, (b) vaccination of pregnant people to help protect newborns in their first months of life, and (c) consideration of vaccination for younger adults at higher risk where recommended by ACIP or local health guidelines. Local availability and insurer coverage can vary, so checking with a primary care clinician or local health department will give you the most actionable guidance.[2][3][6]
If you’d like, I can tailor a concise summary for your specific situation (age, pregnancy status, health conditions) and source the most current local guidance from U.S. authorities. I can also provide a brief quick-reference table of which RSV vaccines are approved for which populations and their key protections, with citations.